aliskiren / Generic mfg. - LARVOL DELTA

Renin-related changes after sequential switching from aliskiren to valsartan and sacubitril/valsartan in patients with a high-renin phenotype: a prospective pilot study. (PubMed, Clin Exp Nephrol) - "In this small prospective pilot study, sequential transition from aliskiren to valsartan and sacubitril/valsartan was associated with renin-related changes without progressive renal deterioration. These preliminary findings may help characterize RAAS-related responses during treatment transition in selected patients with a high-renin phenotype."

Journal • Cardiovascular • Hypertension

From Peptides to Aliskiren: The Evolution of Direct Renin Inhibitors in Hypertension Therapy. (PubMed, Mini Rev Med Chem) - "These findings underscore the complexity of RAAS modulation and the need for continued investigation into DRI pharmacodynamics, tissue-specific effects, and patient stratification. This review focuses on the historical trajectory and molecular refinement of DRIs, highlighting the interplay between structural innovation and therapeutic potential in the quest for more effective hypertension management."

Journal • Cardiovascular • CNS Disorders • Diabetes • Hypertension • Metabolic Disorders • Vascular Neurology

Best-in-class direct renin inhibitor with excellent oral bioavailability and never seen before blood pressure lowering effecacy in monkey (ACS-Fall 2026) - "However, Aliskiren has a low oral bioavailability of 2% to 3% in human, which severely limits its usage. Herein, we would like to report the discovery of a highly potent, safe and orally active renin inhibitor SHEO-054, related medicinal chemistry led to the discovery, PK studies on oral bioavailability in rat (46%) and monkey (56%), and monkey efficacy data (shown)."

Preclinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetic Nephropathy • Heart Failure • Hypertension • Nephrology • Renal Disease

Integrated machine learning and structural bioinformatics guided identification of novel molecular scaffolds as renin inhibitors. (PubMed, Mol Divers) - "Despite extensive research, Aliskiren remains the only clinically approved direct renin inhibitor (DRI), underscoring the necessity for novel scaffolds with improved pharmacokinetic profiles...All four hits exhibited IC50 values between 1.29 µM and 4.19 µM. Among all, HTS00804 demonstrated 53 and 73% renin inhibition in vitro at 1µM and 10 µM concentrations, respectively and can be explored as a starting scaffold for further structural optimization through medicinal chemistry efforts to design next-generation direct renin inhibitors (DRIs)."

Journal • Cardiovascular • Hypertension

Baxdrostat (Baxfendy) - an aldosterone synthase inhibitor for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension

In brief: Widaplik - another three-drug combination for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension

Prevalence of potential primary aldosteronism in patients with heart failure with reduced ejection fraction: a post hoc analysis of the ALOFT trial (HEART FAILURE 2026) - " In this analysis, we included 278 patients with HFrEF enrolled in the ALOFT (ALiskiren Observation of heart Failure Treatment) trial who had available measurements of both PRA and PAC... Potential renin-independent aldosterone production, meeting the criteria for a positive PA screening test, was identified in a substantial proportion of patients with HFrEF, with estimated prevalence ranging from approximately 7% using recent guideline criteria to over 15% with a maximally sensitive screening approach. Possible renin-independent aldosterone production and its significance should be investigated further in HFrEF (and HFpEF)."

Clinical • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

THERAPEUTIC ROLE OF ALISKIREN MONOTHERAPY IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTIHYPERTENSIVE AND ANTIPROTEINURIC EFFECTS (ISPOR 2026) - "Aliskiren monotherapy provides a short-term reduction in blood pressure and a sustained antiproteinuric effect in adults with CKD. While it may serve as an alternative for patients intolerant to ACEIs/ARBs, long-term evidence on its clinical and economic value remains limited. Additional comparative studies are needed to clarify its role in CKD management and quantify its potential impact for payers and health systems."

Monotherapy • Retrospective data • Review • Chronic Kidney Disease • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Region Skane | Active, not recruiting ➔ Recruiting

Enrollment open • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease

A Real-World Disproportionality Analysis of Drug-Induced Heart Failure: Integrating FAERS Database and AHA Statement. (PubMed, Cardiovasc Toxicol) - "Prominent hypoglycemic drugs associated with HF included rosiglitazone, pioglitazone, and saxagliptin...In the context of pulmonary hypertension, drugs like macitentan, selexipag, and epoprostenol were particularly notable...Furthermore, drugs not flagged as positively signaling in the AHA registry, such as amiodarone, aliskiren, and testosterone, merit closer scrutiny due to their potential for adverse reactions. Our analysis of the FAERS database has identified medications associated with potential HF risks, providing valuable evidence to inform clinical decision-making and promote the safe use of medications."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Real-world safety of aliskiren in primary hypertension: A cross-database study. (PubMed, PLoS One) - "This study not only confirms the known adverse reactions of aliskiren but also uncovers new potential risks, highlighting the importance of strengthening drug safety monitoring to enhance therapeutic efficacy and reduce the risk of adverse reactions. It provides valuable safety insights for physicians considering the use of aliskiren in the management of primary hypertension."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Hypertension • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • Respiratory Diseases

Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Blood Pressure and Urinary Protein Excretion Outcomes. (PubMed, J Clin Hypertens (Greenwich)) - "Aliskiren provides a transient decrease in blood pressure and sustained antiproteinuric effect in patients with CKD, although heterogeneous and estimation-dependent. It may be considered an option for individuals intolerant of ACE inhibitors or angiotensin receptor blockers, although evidence on long-term efficacy and safety remains limited."

Clinical • Journal • Monotherapy • Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Hypertension • Hypotension • Nephrology • Renal Disease

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Region Skane | Recruiting ➔ Active, not recruiting

Enrollment closed • Complement-mediated Rare Disorders • Glomerulonephritis

Retraction of: Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy. (PubMed, J Pharm Pharmacol) - No abstract available

Journal • Preclinical • Cardiovascular • Diabetic Nephropathy • Nephrology • Renal Disease

Combined RAS Modulation: The Effect on Plasma and Tissue Angiotensin Peptide Levels. (PubMed, Physiol Res) - "We investigated hemodynamics and circulating and tissue angiotensin peptide profile in spontaneously hypertensive rats (SHR) treated with lisinopril, olmesartan and aliskiren and their dual combinations. Tissue analyses revealed minimal intrinsic Ang II synthesis in the left ventricle, consistent with AT?-dependent uptake of circulating Ang II, while renal peptide profiles indicated some local enzymatic activity with differential reliance on ACE and neprilysin. Our results advocate a cautious, mechanism-aware approach to combination RAS blockade and support therapeutic strategies that balance blood pressure lowering with preservation of the Ang 1-7 axis."

Journal • Cardiovascular • Hypertension • ANGPT1

Choosing wisely in practice: How sick day rules help prevent medication-related complications. (PubMed, Ceska Slov Farm) - "Sick Day Rules provide a unified and applicable framework that can reduce drug-related complications and increase treatment safety in clearly defined situations. Systematic implementation in the Czech environment is feasible and beneficial if accompanied by education and clear instructions for resuming medications. Published literature shows that patients prefer physician-led recommendations."

Journal • Review • Acute Kidney Injury • Nephrology • Renal Disease

Direct Renin Inhibition With Aliskiren Compared to Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Hypertension: A Systematic Review. (PubMed, Cureus) - "Collectively, current evidence suggests that while renin inhibitors may serve as an alternative for patients intolerant to ACEi/ARB, they do not demonstrate clear superiority, and their role may be more relevant in specific subgroups such as obesity-related hypertension or advanced microalbuminuria. Larger, longer-term trials with hard cardiovascular and renal outcomes are warranted to define their optimal place in therapy."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Genetic Disorders • Hypertension • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Renin inhibition improved muscular function by alleviating insulin resistance and AGEs/RAGE signaling in skeletal muscle associated with high glucose: Exploration of renin inhibitor tanshinone IIA. (PubMed, Biochem Pharmacol) - "Tan IIA exhibited direct binding affinity with renin protein, showed the comparable IC50 value as aliskiren on renin inhibitory activity, and inhibited Ang II content and expression of HEK-293 cells...Finally, the type 2 diabetic mice study showed the attenuation of Tan IIA on AGEs accumulation and on RAGE protein expression in muscle, and the in vitro study demonstrated the suppression of Tan IIA on RAGE expression and p38 phosphorylation. The present study indicated that the hyperactivity of RAS in skeletal muscle contributed to the development of diabetes sarcopenia, and that tanshinone IIA possessed the ability in direct inhibition on renin activity, followed by its beneficial effects on skeletal muscle performance and glucose disposal, and its preservation against insulin resistance and AGEs/RAGE signaling in muscle."

Journal • Diabetes • Metabolic Disorders • Sarcopenia • Type 2 Diabetes Mellitus • MEF2C • Myogenin • SLC2A4

Structure-Based Design and In Silico Evaluation of a Lipophilic Cyclooctanoyl- Derivative as a Renin Inhibitor: Lessons from Withdrawn Aliskiren. (PubMed, Int J Mol Sci) - "The MD analysis (200 ns) demonstrated that the inhibitor is anchored via a dual stabilization mechanism: hydrophobic enclosure coupled with persistent ionic interactions. These integrative in silico results highlight the potential of this derivative to overcome Aliskiren's pharmacological shortcomings, providing a strong computational rationale for experimental validation and underscoring the role of structure-based drug design in antihypertensive drug discovery."

Journal • Cardiovascular • Hypertension

Clinician survey for the management of central venous catheter-related bloodstream infection: Catheter retention versus replacement. (PubMed, J Assoc Med Microbiol Infect Dis Can) - "For peripherally inserted central catheter-related BSI, most favoured CVC replacement, although there was variability across pathogens (Candida spp 100%, Staphlococcus aureus 99%; Pseudomonas aeruginosa 94%; Enterococcus spp 75%; Enterobacterales 66%; coagulase-negative staphylococci 58%)...For each combination of pathogen and CVC type, a majority (>50%) of participants reported willingness to enrol patients into an RCT comparing CVC replacement versus retention; the only exceptions below 50% were S. aureus (44%) and Candida spp (44%) CRBSIs from short-term non-tunnelled CVCs. There is heterogeneity in CVC management practices and stated equipoise for an RCT comparing management approaches for a range of CVC types, BSI sources, and pathogens."

Journal • Infectious Disease

Effects of Inhibitors of the Activity of the Circulating Renin-Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells. (PubMed, Int J Mol Sci) - "We then determined the effects of drugs that inhibit the action of renin (VTP-27999 and aliskiren) or angiotensin-converting enzyme (perindoprilat) or block the angiotensin II type 1 receptor (losartan and telmisartan). RAS inhibitors were most effective in Ishikawa cells, which had the highest levels of RAS expression. Therefore, levels of RAS expression in endometrial cancers might indicate the potential efficacy of RAS drugs."

Journal • Endometrial Cancer • Oncology • Solid Tumor

Prevalence of gastrointestinal parasites and their associated risk factors in sheep raised at high and low altitudes in Swat, Pakistan. (PubMed, Open Vet J) - "The number of eggs per gram for Haemonchus spp was 50-1,600epg, Trichuris spp 50-300epg, Taenia spp 50-250epg, Fasciola spp 50-200epg, Moniezia spp 50-150epg, Paramphistomum spp 100-150epg, Dicrocoelium 100-150epg, Filicollis spp 50-150epg, Eimeria spp (oocysts) 50-100epg, and Nematodirus spp 50-100epg, were detected. The current study evidenced higher rates of helminth parasitic infection that can be prevented by ensuring antihelminthic treatments for the sheep population at different intervals."

Journal • Gastrointestinal Disorder • Infectious Disease

Resistant Hypertension in ANCA-Associated Vasculitis: Role for Aliskiren? (KIDNEY WEEK 2025) - "Despite receiving cyclophosphamide and methylprednisolone, he remained dialysis-dependent and was referred for renal transplant. He had multiple hypertensive emergency admissions despite a multi-drug regimen with nifedipine, telmisartan, carvedilol, eplerenone, clonidine, and hydralazine, and dry weight optimization...Studies are warranted to compare DRI efficacy against standard antihypertensives in similar clinical scenarios. The views expressed in this abstract are those of the author(s) and do not necessarily reflect the official policy of the Department of Defense or the U.S. Government."

ANCA Vasculitis • Cardiovascular • Glomerulonephritis • Hypertension • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis • MPO

Potential role of Aliskiren in cancer modulation compared to other Renin-Angiotensin inhibitors: an in-depth review. (PubMed, Eur J Pharmacol) - "While the oncogenic effects of ACEi and ARBs on cancer remain inconclusive, Aliskiren emerges as an antihypertensive drug potentially able to interfere with pro-oncogenic signaling. Nonetheless, its limited evidence base underscores the urgent need for well-designed prospective studies to clarify the differential oncologic impact of various RASi classes across populations. Indeed, cancer patients undergoing long-term RASi deserve close monitoring and multidisciplinary approach for assessment of personalized therapy."

Journal • Review • Cachexia • Cardiovascular • Hypertension • Lung Cancer • Oncology • Renal Disease • Solid Tumor

Prorenin in Hepatic Stellate Cell Extracellular Vesicles Induces Platelet-Dependent Thrombin Formation and Release of Profibrotic TGF-β. (PubMed, FASEB J) - "The aspartyl protease inhibitor pepstatin, or specific inhibitors Aliskiren and VTP23999 of the aspartyl protease renin suppressed HSC EV-induced platelet activation, as did siRNA knockdown of prorenin...This TGF-β stimulated the LX-2 cell TGFbR1 receptor, Smad phosphorylation, and profibrotic protein expression. We identify hitherto undiscovered pathways by which platelet and HSC interaction stimulates thrombosis through prorenin activation and show intrahepatic platelets are positioned to stimulate fibrotic protein deposition in a model of hepatic fibrosis."

Journal • Cardiovascular • Fibrosis • Hematological Disorders • Hepatology • Immunology • Inflammation • Liver Failure • Thrombosis • TGFB1 • TGFBR1